title: Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.
abstract: BACKGROUND
  High dose Epirubicin (HD-EPI) (>90 mg/m2) and Vinorelbine (VNR) demonstrated antitumor activity as single agent (about 20%) in the treatment of advanced NSCLC. This trial compares these two agents combined with cisplatin (CP).
  
  
  METHODS
  From August 1992 to February 1996, 228 patients with locally advanced or metastatic NSCLC were randomized to receive either EPI 120 mg/m2 as i.v. bolus plus Cisplatin (CP) 60 mg/m2 on day 1 (regimen A) or VNR 25 mg/m2 as i.v. bolus on day 1 and 8 plus CP 60 mg/m2 on day 1 (regimen B). Both treatments were recycled every 21 days up to a maximum cumulative dose of EPI of 840 mg/m2 or 12 cycles. Eligible patients were 212 and 198 patients were evaluable for objective response (95 in arm A and 103 in arm B). The main characteristics of eligible patients were: male/female 179/33; median age 61 (42-72); median Karnofsky PS 80 (70-100); stage IIIA 12%, stage IIIB 40%, stage IV 41%, recurrence 7%; histotype: epidermoid 48%, adenoca 36%, others 16%.
  
  
  RESULTS
  The following response rates were observed in regimens A and B, respectively; CR, 1 and 2%, PR, 32 and 25% (P = 0.4567). Median CR + PR duration was 9 and 8 months, respectively. Median survival was 10.5 and 9.6 months, respectively. Grade III-IV leucopenia occurred in 38 and 21% in arm A and arm B, respectively(P = 0.01), thrombocytopenia in 6 and 0% (P = 0.02), anemia in 8 and 7% (n.s.). Non-hematological toxicity was moderate and the only difference between the treatments was alopecia (88 vs. 33% in arm A and B, respectively). Supraventricular arrhythmia occurred in three patients on regimen A; a >15% LVEF absolute decrease was observed in 9 (22.5%) and three (14%) patients on arm A and arm B, respectively (n.s.). No congestive heart failure was observed.
  
  
  CONCLUSIONS
  HD-EPI+CP and VNR+CP are both active combinations in advanced NSCLC with a similar response rate, response duration and survival but regimen A was significantly more toxic (myelosuppression and alopecia).
authors.affiliation: Division of Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Martoni
authors.forename: M
authors.initials: M
authors.lastname: Guaraldi
authors.forename: E
authors.initials: E
authors.lastname: Piana
authors.forename: E
authors.initials: E
authors.lastname: Strocchi
authors.forename: A
authors.initials: A
authors.lastname: Petralia
authors.forename: L
authors.initials: L
authors.lastname: Busutti
authors.forename: P
authors.initials: P
authors.lastname: Preti
authors.forename: G
authors.initials: G
authors.lastname: Robustelli
authors.forename: M
authors.initials: M
authors.lastname: Raimondi
authors.forename: G
authors.initials: G
authors.lastname: Ferrara
authors.forename: G
authors.initials: G
authors.lastname: Palomba
authors.forename: G
authors.initials: G
authors.lastname: Lelli
authors.forename: V
authors.initials: V
authors.lastname: Picece
authors.forename: E
authors.initials: E
authors.lastname: Recaldin
authors.forename: O
authors.initials: O
authors.lastname: Caffo
authors.forename: G
authors.initials: G
authors.lastname: Ambrosini
authors.forename: G
authors.initials: G
authors.lastname: Sarobba
authors.forename: A
authors.initials: A
authors.lastname: Farris
authors.forename: F
authors.initials: F
authors.lastname: Pannuti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007558:Italy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D015251:Epirubicin; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine